Get started
Author

Brent Neil Rexer

Observed names: B N Rexer, B Rexer, B. Rexer, B.N. Rexer, BN Rexer, Brent N Rexer, Brent N. Rexer, Brent Rexer, Rexer BN
Observed institutions: University of North Carolina at Chapel Hill, Beth Israel Deaconess Medical Center, Mayo Clinic, Memorial Sloan Kettering Cancer Center, Harvard University, Eli Lilly (United States), Baylor College of Medicine, Vanderbilt University, Hadassah Medical Center, VA Boston Healthcare System, University of Alabama at Birmingham, Massachusetts General Hospital, Virginia Oncology Associates, Highlands Oncology Group, Hospital Clínic de Barcelona, Dana-Farber Cancer Institute, Hospital Arnau de Vilanova, Solti, University of Pittsburgh Medical Center, Center for Systems Biology, Hospital Universitario Ramón y Cajal, Sidney Kimmel Comprehensive Cancer Center, Vall d'Hebron Institute of Oncology, Moores Cancer Center, Vanderbilt-Ingram Cancer Center, UNC Lineberger Comprehensive Cancer Center, Vanderbilt University Medical Center
ORCID: 0000-0002-0341-7392
Observed ORCID: 0000-0002-0341-7392
OpenAlex ID: A5070245444
Mutations in the phosphatidylinositol 3-kinase pathway: role in tumor progression and therapeutic implications in breast cancer
2011 · Todd W Miller, Brent N Rexer, et al. · Breast Cancer Research · 464
PDF
Intrinsic and Acquired Resistance to HER2-Targeted Therapies in HER2 Gene-Amplified Breast Cancer: Mechanisms and Clinical Implications
2012 · Brent N. Rexer, Carlos L. Arteaga · Critical Reviews™ in Oncogenesis · 372
HER2-Enriched Subtype and ERBB2 Expression in HER2-Positive Breast Cancer Treated with Dual HER2 Blockade
2019 · Aleix Prat, Tomás Pascual, et al. · JNCI Journal of the National Cancer Institute · 175
Phosphoproteomic mass spectrometry profiling links Src family kinases to escape from HER2 tyrosine kinase inhibition
2011 · B N Rexer, A-J L Ham, et al. · Oncogene · 139
H1047R phosphatidylinositol 3-kinase mutant enhances HER2-mediated transformation by heregulin production and activation of HER3
2010 · A Chakrabarty, B N Rexer, et al. · Oncogene · 102
Extracellular Matrix/Integrin Signaling Promotes Resistance to Combined Inhibition of HER2 and PI3K in HER2+ Breast Cancer
2017 · Ariella B. Hanker, Mónica Valeria Estrada, et al. · Cancer Research · 98
Optical imaging of metabolism in HER2 overexpressing breast cancer cells
2011 · Alex Walsh, Rebecca S. Cook, et al. · Biomedical Optics Express · 87
Rictor/mTORC2 Drives Progression and Therapeutic Resistance of HER2 -Amplified Breast Cancers
2016 · Meghan Morrison Joly, Donna J. Hicks, et al. · Cancer Research · 85
Overcoming resistance to tyrosine kinase inhibitors: Lessons learned from cancer cells treated with EGFR antagonists
2009 · Brent N. Rexer, Jeffrey A. Engelman, et al. · Cell Cycle · 82
PDF
Retinol conversion to retinoic acid is impaired in breast cancer cell lines relative to normal cells
2000 · Rafael Mira‐Y‐Lopez, Wen Li Zheng, et al. · Journal of Cellular Physiology · 82
Direct inhibition of PI3K in combination with dual HER2 inhibitors is required for optimal antitumor activity in HER2+ breast cancer cells
2014 · Brent N Rexer, Siprachanh Chanthaphaychith, et al. · Breast Cancer Research · 80
PDF
Retinoic acid biosynthesis by normal human breast epithelium is via aldehyde dehydrogenase 6, absent in MCF-7 cells.
2001 · B N Rexer, W L Zheng, et al. · PubMed · 75
Human Breast Cancer Cells Harboring a Gatekeeper T798M Mutation in HER2 Overexpress EGFR Ligands and Are Sensitive to Dual Inhibition of EGFR and HER2
2013 · Brent N. Rexer, Ritwik Ghosh, et al. · Clinical Cancer Research · 73
Retinoic Acid Does Not Affect Alveolar Septation in Adult FVB Mice with Elastase-Induced Emphysema
2003 · Edgar C. Lucey, Ronald H. Goldstein, et al. · Respiration · 65
Changes in Peripheral and Local Tumor Immunity after Neoadjuvant Chemotherapy Reshape Clinical Outcomes in Patients with Breast Cancer
2020 · Margaret L. Axelrod, Mellissa J. Nixon, et al. · Clinical Cancer Research · 59
TBCRC023: A Randomized Phase II Neoadjuvant Trial of Lapatinib Plus Trastuzumab Without Chemotherapy for 12 versus 24 Weeks in Patients with HER2-Positive Breast Cancer
2019 · Mothaffar F. Rimawi, Polly Niravath, et al. · Clinical Cancer Research · 58
PDF
Evaluating HER2 amplification status and acquired drug resistance in breast cancer cells using Raman spectroscopy
2014 · Xiaohong Bi, Brent Rexer, et al. · Journal of Biomedical Optics · 57
PDF
Optimal Targeting of HER2–PI3K Signaling in Breast Cancer: Mechanistic Insights and Clinical Implications
2013 · Brent N. Rexer, Carlos L. Arteaga · Cancer Research · 51
CRBP suppresses breast cancer cell survival and anchorage-independent growth
2001 · Yuvarani S Kuppumbatti, Brent Rexer, et al. · Oncogene · 51
An ERBB1-3 Neutralizing Antibody Mixture With High Activity Against Drug-Resistant HER2+ Breast Cancers With ERBB Ligand Overexpression
2017 · Luis J Schwarz, Katherine E Hutchinson, et al. · JNCI Journal of the National Cancer Institute · 46
PDF
Inhibition of PI3K and MEK: It Is All about Combinations and Biomarkers
2009 · Brent N. Rexer, Ritwik Ghosh, et al. · Clinical Cancer Research · 40
A Novel Short-Chain Alcohol Dehydrogenase from Rats with Retinol Dehydrogenase Activity, Cyclically Expressed in Uterine Epithelium1
2002 · Brent N. Rexer, David E. Ong · Biology of Reproduction · 36
A phase Ib study of abemaciclib with therapies for metastatic breast cancer.
2015 · Sara M. Tolaney, Muralidhar Beeram, et al. · Journal of Clinical Oncology · 29
Conditional Loss of ErbB3 Delays Mammary Gland Hyperplasia Induced by Mutant PIK3CA without Affecting Mammary Tumor Latency, Gene Expression, or Signaling
2013 · Christian D. Young, Adam D. Pfefferle, et al. · Cancer Research · 29
Abstract S6-02: TBCRC023: A randomized multicenter phase II neoadjuvant trial of lapatinib plus trastuzumab, with endcorine therapy and without chemotherapy, for 12 vs. 24 weeks in patients with HER2 overexpressing breast cancer
2015 · Mothaffar F Rimawi, Polly A Niravath, et al. · Cancer Research · 27
Works count: 214
Citation count: 2,667
H-index: 25
I10-index: 35
Year
Topic
Type